BioNano Genomics Inc vs Flagstar Bank NA — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Flagstar Bank NA trades at $15.15 (market cap $6.24B). The key difference: Flagstar Bank NA is far larger — about 472.7× BioNano Genomics Inc's market cap, and Flagstar Bank NA pays a 0.27% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | FLG | |
|---|---|---|
Market Cap | $13.20M | $6.24B |
Sector | Health | Financials |
52-Week High | $4.92 | $15.28 |
52-Week Low | $1.09 | $10.72 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 0.27% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Flagstar Bank (FLG) trades at $14.88, down 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows improving fundamentals with two consecutive quarterly EPS beats and a positive Q1 2026 net income of $0.04 per share. Recent news highlights management's focus on technology transformation and balance sheet stabilization, while the P/B ratio of 0.82 indicates potential undervaluation relative to book value.
The outlook is cautiously optimistic with a consensus price target of $17.05 offering 14.6% upside. Risks include negative net income margins and high interest expenses, but analyst sentiment is positive with no sell ratings. The upcoming Q2 2026 earnings report on July 24, 2026, will be critical for confirming the turnaround trajectory.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →